Company intelligence / Profile preview

OBIGEN Pharma

Tainan City, Tainan, Taiwanobigenpharma.com ↗

Ownership: Private
Development stage: Phase 1

Overview

OBIGEN Pharma is developing OBI-858, a botulinum toxin product that has received halal certification from the Taipei Grand Mosque Foundation due to its formulation being free of animal-derived ingredients and alcohol.

Therapeutic areas: Neurology
Modalities: Botulinum toxin
Industry: Biotech

Drug pipeline

1 asset

OBI-858

Phase 1

Indications: Cosmetic medicine

Partnerships

OBI Pharma (exclusive global medical use license agreement for OBI-858)

Beyond the preview

Go deeper on OBIGEN Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OBIGEN Pharma.

Explore the full profile